Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Author:

Crawford Katharine H D123,Dingens Adam S1,Eguia Rachel1,Wolf Caitlin R4,Wilcox Naomi4,Logue Jennifer K4,Shuey Kiel4,Casto Amanda M4,Fiala Brooke56,Wrenn Samuel56,Pettie Deleah56,King Neil P56,Greninger Alexander L78,Chu Helen Y4,Bloom Jesse D129ORCID

Affiliation:

1. Division of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

2. Department of Genome Sciences, University of Washington, Seattle, Washington, USA

3. Medical Scientist Training Program, University of Washington, Seattle, Washington, USA

4. Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA

5. Department of Biochemistry, University of Washington, Seattle, Washington, USA

6. Institute for Protein Design, University of Washington, Seattle, Washington, USA

7. Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington, USA

8. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

9. Howard Hughes Medical Institute, Seattle, Washington, USA

Abstract

Abstract Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop neutralizing antibodies that target the viral spike protein. In this study, we quantified how levels of these antibodies change in the months after SARS-CoV-2 infection by examining longitudinal samples collected approximately 30–152 days after symptom onset from a prospective cohort of 32 recovered individuals with asymptomatic, mild, or moderate-severe disease. Neutralizing antibody titers declined an average of about 4-fold from 1 to 4 months after symptom onset. This decline in neutralizing antibody titers was accompanied by a decline in total antibodies capable of binding the viral spike protein or its receptor-binding domain. Importantly, our data are consistent with the expected early immune response to viral infection, where an initial peak in antibody levels is followed by a decline to a lower plateau. Additional studies of long-lived B cells and antibody titers over longer time frames are necessary to determine the durability of immunity to SARS-CoV-2.

Funder

National Institute of Allergy and Infectious Diseases

National Institutes of Health

Bill and Melinda Gates Foundation

Burroughs Wellcome Fund

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Reference47 articles.

1. Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients;Wang;Clin Infect Dis

2. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections [Accepted Author Manuscript];Lei;Allergy,2020

3. Antibody responses to SARS-CoV-2 in patients with COVID-19;Long;Nat Med,2020

4. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection.;Seow;medRxiv [Preprint]. 11 July,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3